AUTHOR=Jaylet Thomas , Coustillet Thibaut , Smith Nicola M. , Viviani Barbara , Lindeman Birgitte , Vergauwen Lucia , Myhre Oddvar , Yarar Nurettin , Gostner Johanna M. , Monfort-Lanzas Pablo , Jornod Florence , Holbech Henrik , Coumoul Xavier , Sarigiannis Dimosthenis A. , Antczak Philipp , Bal-Price Anna , Fritsche Ellen , Kuchovska Eliska , Stratidakis Antonios K. , Barouki Robert , Kim Min Ji , Taboureau Olivier , Wojewodzic Marcin W. , Knapen Dries , Audouze Karine 

TITLE=Comprehensive mapping of the AOP-Wiki database: identifying biological and disease gaps

JOURNAL=Frontiers in Toxicology

VOLUME=6

YEAR=2024

URL=https://www.frontiersin.org/journals/toxicology/articles/10.3389/ftox.2024.1285768

DOI=10.3389/ftox.2024.1285768

ISSN=2673-3080

ABSTRACT=<p><bold>Introduction:</bold> The Adverse Outcome Pathway (AOP) concept facilitates rapid hazard assessment for human health risks. AOPs are constantly evolving, their number is growing, and they are referenced in the AOP-Wiki database, which is supported by the OECD. Here, we present a study that aims at identifying well-defined biological areas, as well as gaps within the AOP-Wiki for future research needs. It does not intend to provide a systematic and comprehensive summary of the available literature on AOPs but summarizes and maps biological knowledge and diseases represented by the already developed AOPs (with OECD endorsed status or under validation).</p><p><bold>Methods:</bold> Knowledge from the AOP-Wiki database were extracted and prepared for analysis using a multi-step procedure. An automatic mapping of the existing information on AOPs (i.e., genes/proteins and diseases) was performed using bioinformatics tools (i.e., overrepresentation analysis using Gene Ontology and DisGeNET), allowing both the classification of AOPs and the development of AOP networks (AOPN).</p><p><bold>Results:</bold> AOPs related to diseases of the genitourinary system, neoplasms and developmental anomalies are the most frequently investigated on the AOP-Wiki. An evaluation of the three priority cases (i.e., immunotoxicity and non-genotoxic carcinogenesis, endocrine and metabolic disruption, and developmental and adult neurotoxicity) of the EU-funded PARC project (Partnership for the Risk Assessment of Chemicals) are presented. These were used to highlight under- and over-represented adverse outcomes and to identify and prioritize gaps for further research.</p><p><bold>Discussion:</bold> These results contribute to a more comprehensive understanding of the adverse effects associated with the molecular events in AOPs, and aid in refining risk assessment for stressors and mitigation strategies. Moreover, the FAIRness (i.e., data which meets principles of findability, accessibility, interoperability, and reusability (FAIR)) of the AOPs appears to be an important consideration for further development.</p>